FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Alzheimer's related Press Releases

AstraZeneca PLC (AZN) and Targacept, Inc. (TRGT) Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Diseas

AstraZeneca PLC (AZN) and Targacept, Inc. (TRGT) Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease AstraZeneca and Targacept, Inc. today announced that results from... Read more...

PRESS RELEASE: Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases

Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Cambridge, MA and Zürich, Switzerland, November 20, 2007 – Biogen Idec and Neurimmune... Read more...

PRESS RELEASE: Children With Alzheimer's Disease Risk Gene Show Reduced Cognitive Function

Children With Alzheimer's Disease Risk Gene Show Reduced Cognitive Function Children who possess a gene known to increase the risk of Alzheimer's disease already show signs of reduced cognitive... Read more...

PRESS RELEASE: An Alzheimer’s Vaccine?

Oklahoma City, Nov. 12, 2007 – Could a new vaccine be the key to stopping Alzheimer’s disease? A new research study from the Oklahoma Medical Research Foundation shows that immunization could... Read more...

PRESS RELEASE: Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease

Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease MONTVALE, N.J., Nov. 2 -- Memory Pharmaceuticals Corp. today announced positive top-line data from the... Read more...

PRESS RELEASE: UCLA scientists pinpoint a possible physical origin of Alzheimer's disease

UCLA scientists pinpoint a possible physical origin of Alzheimer's disease Discovery suggests new ways to treat disorder's cause, not just symptoms FINDINGS: For some time, scientists have blamed... Read more...

PRESS RELEASE: Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease MONTVALE, N.J., Oct. 15 -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced top-line data... Read more...

PRESS RELEASE: Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis

Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis Ranbaxy will benefit from the 180 day shared exclusivity on the product PRINCETON, N.J. --... Read more...

PRESS RELEASE: Baxter to Pursue a Phase III Study of Gammagard

Baxter and the Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer's Disease  Preliminary Phase II Results Encouraging and Support... Read more...